...
首页> 外文期刊>The biochemical journal >Structural determinants of human proton-coupled folate transporter oligomerization: role of GXXXG motifs and identification of oligomeric interfaces at transmembrane domains 3 and 6
【24h】

Structural determinants of human proton-coupled folate transporter oligomerization: role of GXXXG motifs and identification of oligomeric interfaces at transmembrane domains 3 and 6

机译:人质子偶联的叶酸转运蛋白低聚的结构决定因素:GXXXG图案的作用和跨膜结构域3和6的寡聚界面的鉴定

获取原文
   

获取外文期刊封面封底 >>

       

摘要

pThe human proton-coupled folate transporter (hPCFT) is expressed in solid tumours and is active at pHs characterizing the tumour microenvironment. Recent attention focused on exploiting hPCFT for targeting solid tumours with novel cytotoxic anti-folates. hPCFT has 12 transmembrane domains (TMDs) and forms homo-oligomers with functional significance. The hPCFT primary sequence includes GXXXG motifs in TMD2 (Gsup93/supXXXGsup97/sup) and TMD4 (Gsup155/supXXXGsup159/sup). To investigate roles of these motifs in hPCFT function, stability and surface expression, we mutated glycine to leucine to generate single or multiple substitution mutants. Only the G93L and G159L mutants preserved substantial [sup3/supH]methotrexate (Mtx) transport when expressed in hPCFT-null (R1-11) HeLa cells. Transport activity of the glycine-to-leucine mutants correlated with surface hPCFT by surface biotinylation and confocal microscopy with ECFP*-tagged hPCFTs, suggesting a role for GXXXG in hPCFT stability and intracellular trafficking. When co-expressed in R1-11 cells, haemagglutinin-tagged glycine-to-leucine mutants and Hissub10/sub-tagged wild-type (WT) hPCFT co-associated on nickel affinity columns, suggesting that the GXXXG motifs are not directly involved in hPCFT oligomerization. This was substantiated by iin situ/i FRET experiments with co-expressed ECFP*- and YFP-tagged hPCFT. Molecular modelling of dimeric hPCFT structures showed juxtaposed TMDs 2, 3, 4 and 6 as potential structural interfaces between monomers. hPCFT cysteine insertion mutants in TMD3 (Q136C and L137C) and TMD6 (W213C, L214C, L224C, A227C, F228C, F230C and G231C) were expressed in R1-11 cells and cross-linked with 1,6-hexanediyl ibis/imethanethiosulfonate, confirming TMD juxtapositions. Altogether, our results imply that TMDs 3 and 6 provide critical interfaces for formation of hPCFT oligomers, which might be facilitated by the GXXXG motifs in TMD2 and TMD4./p
机译:>人质子偶联叶酸转运蛋白(hPCFT)在实体瘤中表达,并在表征肿瘤微环境的pH值下具有活性。最近的注意力集中在利用hPCFT靶向具有新型细胞毒性抗叶酸的实体瘤上。 hPCFT具有12个跨膜结构域(TMD),并形成具有功能意义的同型低聚物。 hPCFT主序列在TMD2(G 93 XXXG 97 )和TMD4(G 155 XXXG 159 )中包含GXXXG基序)。为了研究这些基序在hPCFT功能,稳定性和表面表达中的作用,我们将甘氨酸突变为亮氨酸以生成单个或多个取代突变体。当在hPCFT无效(R1-11)HeLa细胞中表达时,只有G93L和G159L突变体保留了大量的[ 3 H]甲氨蝶呤(Mtx)转运。甘氨酸到亮氨酸突变体的转运活性通过表面生物素化和带ECFP *标签的hPCFT的共聚焦显微镜与表面hPCFT相关,提示GXXXG在hPCFT稳定性和细胞内运输中的作用。当在R1-11细胞中共表达时,血凝素标记的甘氨酸转为亮氨酸突变体和His 10 标记的野生型(WT)hPCFT在镍亲和柱上共缔合,表明GXXXG基序不直接参与hPCFT寡聚。这是通过在原位FRET实验中共表达ECFP *和YFP标签的hPCFT证实的。二聚体hPCFT结构的分子模型显示并列的TMDs 2、3、4和6是单体之间潜在的结构界面。在R1-11细胞中表达了TMD3(Q136C和L137C)和TMD6(W213C,L214C,L224C,A227C,F228C,F230C和G231C)中的hPCFT半胱氨酸插入突变体,并与1,6-己二基 bis <甲硫代磺酸盐,确认TMD并置。总之,我们的结果表明TMD 3和6为hPCFT低聚物的形成提供了关键的界面,而TMD2和TMD4中的GXXXG基序可能会促进这一过程。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号